On September 12, AstraZeneca PLC declined 3.65% in after-hours trading, with shares dropping to approximately $155.00 per share on turnover of $2.64 million.

The decline was triggered by disappointing results from a Phase 3 clinical trial. The setback adds to a series of mixed clinical developments for the company, which earlier terminated its Phase 3 lung cancer trial for volrustomig after an independent data monitoring committee found the combination therapy was unlikely to meet its primary survival endpoints in metastatic non-small cell lung cancer patients.

Within the Pharmacy sector, peers showed relatively muted moves during the regular session, with Eli Lilly up 0.12%, Johnson & Johnson up 0.41%, Merck up 0.05%, Pfizer down 0.10%, and Novo-Nordisk down 0.01%, underscoring that AstraZeneca's after-hours weakness was driven by company-specific clinical news rather than broader sector pressure.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)